Sigilon Therapeutics, Inc. (46) | License Agreements (7)
Recent Contracts
-
Sixth Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated February 1, 2022
(Filed With SEC on March 14, 2022)
-
Fifth Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated September 17, 2021
(Filed With SEC on November 10, 2021)
-
Fourth Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated December 10, 2020
(Filed With SEC on March 18, 2021)
-
Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated February 8, 2016
(Filed With SEC on November 13, 2020)
-
First Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated February 2, 2017
(Filed With SEC on November 13, 2020)
-
Second Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated August 9, 2018
(Filed With SEC on November 13, 2020)
-
Third Amendment to Exclusive Patent License Agreement, by and between Massachusetts Institute of Technology and Sigilon Therapeutics, Inc., dated November 6, 2019
(Filed With SEC on November 13, 2020)
